- Details
- In this conversation, Pedro Barata interviews Toni Choueiri, discussing the combination of cabozantinib with belzutifan in patients with advanced clear cell renal cell carcinoma (RCC). The study focused on two cohorts: one in the refractory setting and the other in the treatment-naive setting. Dr. Choueiri explains the rationale behind combining a HIF-2 inhibitor with a TKI and why cabozantinib wa...
|
- Details
- Manish Kohli joins Pedro Barata to discuss a cost-effectiveness analysis of six IO-based regimens plus Sunitinib in patients with metastatic renal cell carcinoma, a paper published in JCO Oncology Practice. A cost-effectiveness analysis was performed to determine the optimal therapy for metastatic renal cell carcinoma (mRCC) based on cost and health outcomes. The analysis included treatment drug s...
|
- Details
- Yann Vano joins Pedro Barata to discuss the overall survival and efficacy results from the randomized phase II BIONIKK trial of second-line treatment for patients with metastatic clear cell renal cell carcinoma (mRCC). The trial included patients with ccrc1-4 tumors and randomized them to receive nivo, nivo-ipi, or VEGFR-TKI. In the 18-month follow-up the study showed that nivo-based therapies wer...
|
- Details
- Pedro Barata and Mauricio Burotto discuss the 3-year follow-up of the CheckMate-9ER study. This study compares the combination of nivolumab plus cabozantinib with sunitinib for first-line treatment of advanced renal cell carcinoma (RCC). Nivolumab plus cabozantinib maintained survival and response benefits after 3 years of follow-up. Median overall survival with nivolumab plus cabozantinib improve...
|
- Details
- Laurence Albiges joins Pedro Barata to discuss the CaboPoint study, a clinical trial designed to examine the question of activity and safety of cabozantinib single agent in patients who failed first-line combination therapy for advanced renal cell carcinoma (aRCC). The study has two subgroups - Cohort A and Cohort B. Cohort A is the activity of cabozantinib after nivolumab/pembrolizumab, and Cohor...
|
- Details
- Bradley McGregor joins Pedro Barata in a conversation to discuss the results of the COSMIC-021 study, which looked at the combination of cabozantinib with atezolizumab for non-clear-cell, renal cell carcinoma. The study showed clinical activity for the combination of cabozantinib and atezolizumab across the 32 patients with variant-histology renal cell carcinoma, with no new toxicity signals. The...
|
- Details
- Michael Atkins joins Pedro Barata in a conversation on Cohort A of a phase II study looking at treatment-free survival (TFS) outcomes of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260). This study was designed to potentially reduce the toxicity by sparing people ipi who didn't need it and also capping therapy in patients who were having a lo...
|
- Details
- In this conversation, Pedro Barata and Andrea Apolo highlight an exploratory analysis of the CheckMate 9ER trial in patients with previously untreated advanced renal cell carcinoma (aRCC), looking at the association between depth of response and clinical outcomes with extended follow-up (minimum 25.4 months; median 32.9 months). In January 2021, the Food and Drug Administration (FDA) approved the...
|
- Details
- Thomas Powles discusses the results of the CALYPSO trial with Pedro Barata. Dr. Powles provides an overview of the trial design of this international, multicentre, open-label phase Ib/IIa study of durvalumab alone, savolitinib alone, and durvalumab in combination with savolitinib or tremelimumab in patients with metastatic renal cell cancer. He then discusses the trial results, plus his thoughts o...
|
- Details
- Deepak Kilari joins Pedro Barata in a discussion on the ORACLE study, which investigates the efficacy of combination systemic therapies in patients with advanced non-clear cell renal cell carcinoma. Dr. Kilari gives an overview of the trial design and shares his hopes and goals for the future of this trial as it continues to expand to more institutions and provide a larger, more robust data set. B...
|
